How should we dose antibiotics for pneumonia in the ICU?

Current Opinion in Infectious Diseases

Volumn 26, Issue 2, 2013, Pages 189-195

  Udy, Andrew A ^a,b   Roberts, Jason A ^a,b   Lipman, Jeffrey ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Antibiotics; Critical illness; Dosing; Pneumonia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; LINEZOLID; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; CLINICAL RESEARCH; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; FLUID RESUSCITATION; HUMAN; INTENSIVE CARE UNIT; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PRESCRIPTION; REVIEW;

ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; HUMANS; INTENSIVE CARE UNITS; PNEUMONIA;

EID: 84874932358     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32835d19e0     Document Type: Review

References (40)

1. Piskin N, Aydemir H, Oztoprak N, et al. Inadequate treatment of ventilatorassociated and hospital-acquired pneumonia: Risk factors and impact on outcomes. BMC Infect Dis 2012; 12:268.
2. Drusano GL. What are the properties that make an antibiotic acceptable for therapy of community-acquired pneumonia? J Antimicrob Chemother 2011; 66 (Suppl 3):61-67.
3. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37:840-851.
4. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998; 27:10-22.
5. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-99. (Pubitemid 17225088)
6. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42 (Suppl 1):S35-S39. (Pubitemid 41832063)
7. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-1081. (Pubitemid 23141323)
8. Rodvold KA, George JM, Yoo L. Penetration of antiinfective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet 2011; 50:637-664.
9. Chandorkar G, Huntington JA, Gotfried MH, et al. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J Antimicrob Chemother 2012; 67:2463-2469.
10. Lodise TP, Drusano GL, Butterfield JM, et al. Penetration of vancomycin into epithelial lining fluid in healthy volunteers. Antimicrob Agents Chemother 2011; 55:5507-5511.
11. Boselli E, Breilh D, Caillault-Sergent A, et al. Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia. J Antimicrob Chemother 2012; 67:1207-1210.
12. Kontou P, Chatzika K, Pitsiou G, et al. Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. Antimicrob Agents Chemother 2011; 55:4149-4153.
13. Nicolau DP, Sutherland C, Winget D, Baughman RP. Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. Pulm Pharmacol Ther 2012; 25:94-98.
14. Lodise TP, Sorgel F, Melnick D, et al. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2011; 55:1606-1610.
15. Smith BS, Yogaratnam D, Levasseur-Franklin KE, et al. Introduction to drug pharmacokinetics in the critically ill patient. Chest 2012; 141:1327-1336.
16. Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet 2012. [Epub ahead of print]
17. Ulldemolins M, Roberts JA, Rello J, et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011; 50:99-110.
18. Briscoe SE, McWhinney BC, Lipman J, et al. A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 907:178-184.
19. Kees MG, Vogeler S, Hilpert JW. Initial dosing of vancomycin in critically ill patients. Int J Antimicrob Agents 2011; 38:91-92.
20. Goncalves-Pereira J, Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit Care 2011; 15:R206.
21. Li J, Udy AA, Kirkpatrick CM, et al. Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study. Int J Antimicrob Agents 2012; 39:69-72.
22. Udy AA, Roberts JA, Lipman J. Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol 2011; 7:539-543.
23. Grootaert V, Willems L, Debaveye Y, et al. Augmented renal clearance in the critically ill: how to assess kidney function. Ann Pharmacother 2012; 46:952-959.
24. Udy AA, Roberts J, De Waele J, et al. What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents 2012; 39:455-457.
25. Udy AA, Varghese JM, Altukroni M, et al. Sub-therapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012; 42:30-39.
26. Roberts DM, Roberts JA, Roberts MS, et al. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 2012; 40:1523-1528.
27. Choi G, Gomersall CD, Tian Q, et al. Principles of antibacterial dosing in continuous renal replacement therapy. Blood Purif 2010; 30:195-212.
28. Jamal JA, Economou CJ, Lipman J, Roberts JA. Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation. Curr Opin Crit Care 2012; 18:460-471.
29. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillinresistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54:621-629.
30. Chung J, Oh JM, Cho EM, et al. Optimal dose of vancomycin for treating methicillin-resistant Staphylococcus aureus pneumonia in critically ill patients. Anaesth Intensive Care 2011; 39:1030-1037.
31. Baptista JP, Sousa E, Martins PJ, Pimentel JM. Augmented renal clearance in septic patients and implications for vancomycin optimisation. Int J Antimicrob Agents 2012; 39:420-423.
32. Ocampos-Martinez E, Penaccini L, Scolletta S, et al. Determinants of early inadequate vancomycin concentrations during continuous infusion in septic patients. Int J Antimicrob Agents 2012; 39:332-337.
33. Roberts JA, Taccone FS, Udy AA, et al. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 2011; 55:2704-2709.
34. Abdul-Aziz MH, Dulhunty JM, Bellomo R, et al. Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care 2012; 2:37.
35. Jaruratanasirikul S, Wongpoowarak W, Kositpantawong N, et al. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia. Int J Antimicrob Agents 2012; 40:434-439.
36. Chytra I, Stepan M, Benes J, et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care 2012; 16:R113.
37. Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of betalactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2012. [Epub ahead of print]
38. Duszynska W, Taccone FS, Switala M, et al. Continuous infusion of piperacillin/tazobactam in ventilator-associated pneumonia: a pilot study on efficacy and costs. Int J Antimicrob Agents 2012; 39:153-158.
39. Janssen Pharmaceuticals Inc: 'Dear Healthcare Professional' letter. Raritan, NJ: Janssen Pharmaceuticals Inc.; 3 January 2012. http://www.fda.gov/ downloads/Drugs/DrugSafety/UCM286277.pdf. [Accessed 12 February 2012]
40. Roberts JA, Joynt GM, Choi GY, et al. How to optimise antimicrobial prescriptions in the intensive care unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 2012; 39:187-192.